Mini ReviewOpen Access

Cancer Immunogene Therapy: Antisense and Triple Helix Aproach

Volume 3 - Issue 3

**Gabriela Quintero¹, Carlos Rojas², Juan J Rey¹ and Jerzy Trojan*¹**

Author Information Open or Close
- ¹Faculty of Health Sciences, UNAB University, Floridablanca, Colombia
- ²Faculty of Health Sciences, UNAB University, and International Foscal Clinic, Floridablanca, Colombia
*Corresponding author: Jerzy Trojan, Faculty of Health Sciences, UNAB University, Floridablanca, Colombia and INSERM U602, Cancer Center, Paris Sud University, Villejuif, France

Received: March 20, 2018; Published: April 05, 2018

DOI: 10.26717/BJSTR.2018.03.000919

Full Text PDF

To view the Full Article Peer-reviewed Article PDF

Abstract

Cellular immunogene therapy inducing immune anti-tumor response constitutes one of the latest strategies for the treatment of many forms of cancers. From 2015, the cancer immunotherapy became an obligatory complement therapy in USA: The Cancer Moonshot Task program supervised by USA government and the cancer immunotherapy program established in Parker Institute in Los Angeles-the common program of the best university hospitals in USA [1]. The beginning of our Anti-gene (antisense and triple helix) IGF-I cellular immunogene Phase I trial in USA and Europe has presented promising results: an increase in immune response goes together with life span, and confirms the role of the immune phenomenon in the suppressing of animal tumors treated experimentally by the same cellular immunogene therapy. We need to underline, that our clinical trial was realized following the establishment of immunogene therapy as a clinical domain. This approach is based on suppression of growth factor IGF-I in cancers cells [2-5].

Introduction| References|